


Product Name : eFT226
Cat. No. : PC-63308
CAS No. : 2098191-53-6
Molecular Formula : C₂₈H₂₉N₃O₅
Molecular Weight : 487.55
Target : Eukaryotic Initiation Factor (eIF)
Solubility : 10 mM in DMSO



Biological Activity

Zotatifin (eFT226) is a novel, potent and selective **eIF4A** inhibitor with anti-tumor activity in B-cell malignancies, promotes eIF4A binding to specific mRNA sequences and interferes with the assembly of the eIF4F initiation complex.

Zotatifin (eFT226) selectively inhibits translation of mRNAs containing longer 5'-UTRs, an increased frequency of uORFs (upstream open reading frame), and polypurine and/or G-quadruplex recognition motifs.

Zotatifin (eFT226) demonstrates potent inhibition of reporter constructs containing a polypurine motif in the 5'-UTR with IC₅₀ of 2 nM.

Zotatifin (eFT226) shows potent anti-proliferative activity (EC₅₀<15 nM) and an induction of apoptosis against a panel of B-cell lymphoma cell lines, dose-dependently decreases the oncogenic drivers c-MYC, CCND1/3, BCL2 or MCL-1.

Zotatifin (eFT226) shows in vivo activity across hematological tumor models.

References

Peggy A. Thompson, et al. Preclinical Evaluation of eFT226, a Novel, Potent and Selective eIF4A Inhibitor with Anti-tumor Activity in B-cell Malignancies.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com